Expand BMRN Menu
BMRN MENU

BMRN Latest Press Releases

-- October 5, 2026 --

BioMarin Appoints Cara Bauer as Chief People Officer PRNewswire 4:05 PM

-- October 2, 2026 --

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress PRNewswire 11:00 AM

-- September 14, 2026 --

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors PRNewswire 9:05 AM

-- September 9, 2026 --

BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence PRNewswire 9:05 AM

-- September 2, 2026 --

BioMarin to Participate in Upcoming Investor Conferences PRNewswire 9:00 AM

-- September 1, 2026 --

BioMarin Announces Close of the Alesta Therapeutics Acquisition PRNewswire 9:05 AM

-- August 31, 2026 --

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea PRNewswire 2:00 AM

-- August 18, 2026 --

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline PRNewswire 8:30 AM

-- August 10, 2026 --

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston PRNewswire 9:05 AM

-- August 6, 2026 --

BioMarin Reports Second Quarter 2026 Financial and Operating Results PRNewswire 4:03 PM

-- July 30, 2026 --

BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET PRNewswire 9:01 AM

-- July 27, 2026 --

BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome PRNewswire 9:05 AM

-- July 13, 2026 --

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia PRNewswire 9:05 AM

-- June 16, 2026 --

BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 PRNewswire 9:05 AM

-- May 20, 2026 --

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia PRNewswire 4:20 PM

-- May 18, 2026 --

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency PRNewswire 9:05 AM
Market Data Delayed 15 Minutes